Norway - LC-MS/MS reagents for screening newborn babies for congenital diseases as well as diagnostics and monitoring PKU patients at OUS

Description

The aim of the procurement is to meet the Newborn Screening Department´s need for LC-MS/MS reagent kits for screening newborn babies for Phenylketonuria (PKU), Propionic acidemia (PA), Metylmalon acidemia (MMA), Isovalerianic acidemia (IVA), Holokarboksylase syntase defect (HCS/MCD), Beta-ketothiolase defect (BKT), Glutarsyreuri type 1 (GA1), Mellomkjedet acyl-CoA-dehydrogenase defect (MCAD), Langkjedet 3-hydroksyacyl-CoA-dehydrogenase defect (LCHAD), Tri-functional protein defect (TFP), Meget langkjedet acyl-CoA- dehydrogenase defect (VLCAD), Karnitin-transporter defect (CTD), Karnitin-palmitoyltransferase I-defect (CTP IA), Karnitin-palmitoyltransferase II-defect (CTP II), Karnitin acylkarnitin-tranlokase defect (CACT), Glutarsyreuri type 2 (GA2), Homocystinuri/Hypermetioninemi (HCU/MET), Tyrosinemi type I (TYR I), and 3-OH 3-metylglutaryl-CoA lyase defect (HMG), as well as diagnostics and monitoring of PKU patients.

We would also like to be able to test for ADA-SCID, but this is not a requirement.

The Newborn Screening Department currently analyses approx.

60 000 samples of filter sample cards and 3500 PKU samples from patients per annum.

Estimated scope and value:

- Approx. 60,000 samples per annum for screening newborn babies

- Approx. 3,500 PKU samples per annum, which are analysed in duplicate for patient monitoring.

Opportunity closing date

07 September 2018

Value of contract

£0-100k